CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

BACKGROUND: Minimal residual disease is the main issue of advanced ovarian cancer treatment. According to the literature and previous results, we hypothesized that Mesenchymal Stromal Cells (MSC) could support this minimal residual disease by protecting ovarian cancer cells (OCC) from chemotherapy....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer
Egile Nagusiak: Pasquier, Jennifer, Gosset, Marie, Geyl, Caroline, Hoarau-Véchot, Jessica, Chevrot, Audrey, Pocard, Marc, Mirshahi, Massoud, Lis, Raphael, Rafii, Arash, Touboul, Cyril
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817856/
https://ncbi.nlm.nih.gov/pubmed/29455640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0787-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak